Mumbai, Jan 18 (UNI) Pharma major Lupin Limited (Lupin) on Saturday announced the completion of an inspection carried out by the United States Food and Drug Administration (USFDA) at its Vizag API manufacturing facility.
The inspection was carried out between January 13, 2020 and January 17, 2020, company said in a filing with BSE.
The inspection for the API facility at Vizag closed with five 483 observations.
Commenting on the outcome of the inspection, Nilesh Gupta, Managing Director, Lupin said, "We are fully committed to adherence with CGMP regulations and uphold high quality standards across all our manufacturing sites. We are confident of addressing the observations to the US FDA's satisfaction".
UNI JS SV 1232